Aditxt Inc (NASDAQ: ADTX) is a clinical-stage biotechnology company developing immune-monitoring and disease-screening technologies. The company operates through its subsidiary Pearsanta, which acquired the assets of MDNA Life Sciences, Inc. on January 4, 2024, including the Mitomic Technology platform, patents, and intellectual property focused on mitochondrial DNA (mtDNA) based biomarkers. Pearsanta has two product candidates in development as of the 10-K filed March 31, 2026: a potential test for prostate cancer diagnosis and a potential test for detection of endometriosis. Neither product has received FDA or foreign regulatory approval, and no products are commercially available. The company has identified mtDNA-based biomarkers it believes are associated with ovarian cancer and lung cancer, and intends to pursue biomarker identification for pancreatic, liver, breast, stomach, esophageal, and colorectal cancers. Aditxt is a smaller reporting company and as of the filing date faced Nasdaq continued listing compliance requirements related to stockholders' equity.

Revenue model

The filing excerpts do not disclose a commercial revenue model. Aditxt has no FDA-approved or commercially available products as of the 10-K filed March 31, 2026. The company is pre-revenue in its Pearsanta diagnostics segment.

Products and services

Pearsanta subsidiary: Mitomic Technology platform for mtDNA-based biomarker research and discovery (acquired from MDNA Life Sciences, Inc., January 4, 2024). Two in-development product candidates: prostate cancer diagnostic test and endometriosis detection test. Early-stage biomarker identification programs targeting ovarian cancer, lung cancer, pancreatic, liver, breast, stomach, esophageal, and colorectal cancers. No commercially available FDA-approved products as of the 10-K filed March 31, 2026.

Customers and end markets

The filing excerpts do not identify specific customers or commercial end markets. Target end markets, if products receive regulatory approval, would be cancer screening and diagnostics.

Value-chain role

Early-stage biotech developer and diagnostics platform acquirer. Aditxt occupies the research, biomarker discovery, and pre-clinical/clinical development stages of the diagnostics value chain. It relies on employees and third-party consultants for operations and has no manufacturing or commercial distribution disclosed in the excerpts.

Geographic exposure

The filing excerpts do not specify geographic markets or revenue by region. The company is incorporated in Delaware and operates as a U.S.-listed entity on Nasdaq.

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations Peers: Acorda Therapeutics, Inc. Benitec Biopharma Inc Panbela Therapeutics, Inc. Statera Biopharma, Inc. CONTRAFECT Corp Creative Medical Technology Holdings Inc Xenetic Biosciences Inc NAVIDEA BIOPHARMACEUTICALS, INC. Dogwood Therapeutics Inc